doi: 10.1097/PRS.0b013e3182450b47 41 ShimizuYShibataRIshiiMOhashiKKambaraTUemuraYet al
Thus, trial results support high-potency GLP-1 RAs and dual GIP and GLP-1 RA as the preferred options for individuals requiring more intensive glucose management ( Fig
First-time prescribing of AOMs also decreased in September 2025, relative to June 2025 (-9.5%)
This typically includes thyroid function tests (TSH, free T4), fasting glucose and hemoglobin A1c, lipid panel, and potentially cortisol levels if Cushing's syndrome is suspected
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C,
The next generation of trials will determine whether histologic and biochemical benefits translate into clinical outcomes such as reduced progression to cirrhosis, decompensation, and cardiovascular events